Trial Profile
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational
- Acronyms SELECTIONLTE
- Sponsors Galapagos NV
- 15 Dec 2023 This trial has been completed in France, according to the European Clinical Trials Database record.
- 02 Nov 2023 This trial has been completed in Czechia, according to the European Clinical Trials Database record.
- 28 Oct 2023 This trial has been completed in Germany, according to the European Clinical Trials Database record.